NASDAQ · FENC
Fennec Pharmaceuticals Inc.
$10.95+$0.08 (+0.74%)
Fennec Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.36% below the high.
Loading market information…
NASDAQ · DERM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Journey Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 43.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Journey Medical Corporation’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Journey Medical Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 14, 2025 | -$0.18+25.0% vs estimate | $13.14M-12.01% vs estimate |
|---|
| Q4 2024 | Mar 26, 2025 | $0.08+136.36% vs estimate | $13.62M+12.99% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.12+29.41% vs estimate | $14.63M+2.93% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.95+$0.08 (+0.74%)
Fennec Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.36% below the high.
$6.09+$0.10 (+1.67%)
Orchestra BioMed Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.31% below the high.
$4.08-$0.02 (-0.49%)
OraSure Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.92% below the high.
$6.75+$0.06 (+0.9%)
Cartesian Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.65% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
$13.86+$0.30 (+2.21%)
MediWound Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.64% below the high.
$0.96+$0.01 (+0.54%)
Organigram Global Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.12% below the high.
$2.26-$0.03 (-1.31%)
Solana Company’s quoted price sits in the lower half of its reported 52-week range, 66.27% below the high.
